Multimodal imaging of bone metastases: From preclinical to clinical applications

Item

http://www.wikidata.org/entity/Q56156782

description

scientific article published on 13 August 2015

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2015

@uk

name

Multimodal imaging of bone metastases: From preclinical to clinical applications

@en

Multimodal imaging of bone metastases: From preclinical to clinical applications

@nl

type

Item

label

Multimodal imaging of bone metastases: From preclinical to clinical applications

@en

Multimodal imaging of bone metastases: From preclinical to clinical applications

@nl

prefLabel

Multimodal imaging of bone metastases: From preclinical to clinical applications

@en

Multimodal imaging of bone metastases: From preclinical to clinical applications

@nl

P1476

Multimodal imaging of bone metastases: From preclinical to clinical applications

@en

P2093

Michael Beck

http://www.w3.org/2001/XMLSchema#string

Michael Uder

http://www.w3.org/2001/XMLSchema#string

Tobias Bäuerle

http://www.w3.org/2001/XMLSchema#string

Torsten Kuwert

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo near-infrared fluorescence imaging of osteoblastic activity

Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 A

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

In vivo molecular target assessment of matrix metalloproteinase inhibition.

Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.

Treatment of metastatic bone disease in breast cancer: bisphosphonates.

P304

166-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JOT.2015.07.004

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stephan Ellmann

P577

2015-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281846178

http://www.w3.org/2001/XMLSchema#string

P698

30035055

http://www.w3.org/2001/XMLSchema#string

P932

5986987

http://www.w3.org/2001/XMLSchema#string